Alkermes Medicines & Focus: Serious Mental Illness

Alkermes Medicines & Focus: Serious Mental Illness

We are committed to addressing unmet needs in serious mental illness through the development of therapeutic options to support adults living with schizophrenia and bipolar I disorder.

Content from this campaign

How To Better Support Individuals With Bipolar 1 Disorder
We’re committed to listening to mental health providers and learning how we can better help them support individuals with bipolar 1 disorder. Our survey of psychiatrists conducted with The Harris Poll & Depression and Bipolar Support Alliance – National Headquarters uncovered varying answers for why individuals may stop taking their medication. About Alkermes...
Jun 27, 2022 1:00 PM ET
Alkermes Honor Men's Mental Health
Fact: compared to women, men are less likely to seek support and services for mental illness. This Men's Health Month, Alkermes encourages its followers to join the movement to amplify Men's Mental Health information and resources....
Jun 16, 2022 1:15 PM ET
New Findings About Life With Bipolar 1 Disorder
Results from our survey conducted with The Harris Poll & ...
May 27, 2022 10:50 AM ET
Treating Bipolar 1 Disorder
Check out a new infographic with findings from our latest survey conducted in partnership with The Harris Poll and Depression and Bipolar Support Alliance – National Headquarters. Learn what healthcare...
May 24, 2022 9:00 AM ET
Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month
DUBLIN, May 6, 2022 /3BL Media/ - Alkermes plc (Nasdaq: ALKS) announced plans to present research related to its psychiatry portfolio at four scientific conferences during Mental Health Awareness Month in May. The meetings include: American Telemedicine Association (ATA) Annual Conference, Boston ...
May 6, 2022 1:05 PM ET

Pages